Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
Sign Up to like & getrecommendations! Published in 2018 at "BMC Veterinary Research"
DOI: 10.1186/s12917-018-1587-9
Abstract: BackgroundChemotherapeutic options for the treatment of canine lymphoma have not changed in several decades necessitating the identification of new therapeutics to improve patient outcome. KPT-335 (verdinexor) is a novel orally bioavailable selective inhibitor of nuclear… read more here.
Keywords: lymphoma; 335 verdinexor; kpt 335; phase study ... See more keywords